Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting

References

• FratiglioniLLaunerLJAndersenKIncidence of dementia and major subtypes in Europe: A collaborative study of population-based cohortsNeurology200054Suppl 51015
   Google Scholar
• FratiglioniLDe RonchiDAgüero-TorresHWorldwide prevalence and incidence of dementiaDrugs Aging19991536537510600044
   PubMed Web of Science ®Google Scholar
• ChristensenKDoblhammerGRauRVaupelJWAgeing populations: the challenges aheadLancet20093741196120819801098
   PubMed Web of Science ®Google Scholar
• GalaskoDEdlandSDMorrisJCClarkCMohsRKossEThe Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part XI. Clinical milestones in patients with Alzheimer’s disease followed over 3 yearsNeurology199545145114557644039
   PubMed Web of Science ®Google Scholar
• BurnsAO’BrienJAuriacombeSon behalf of the BAP Dementia Consensus GroupClinical practice with anti-dementia drugs: a consensus statement from British Association for PsychopharmacologyJ Psychopharmacol20062073275517060346
   PubMed Web of Science ®Google Scholar
• SamochockiMZerlinMJostockRGalantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChRActa Neurol Scand Suppl200017673
   Google Scholar
• LoyCSchneiderLGalantamine for Alzheimer’s disease and mild cognitive impairmentCochrane Database Syst Rev20061CD00174716437436
   PubMed Web of Science ®Google Scholar
• TariotPNSolomonPRMorrisJCKershawPLilienfeldSDingCA 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study GroupNeurology200052269227610881251
   PubMed Web of Science ®Google Scholar
• RaskindMAPeskindERWesselTYuanWGalantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study GroupNeurology2000542261226810881250
   PubMed Web of Science ®Google Scholar
• LanctôtKLHerrmannNLouLouMMCorrelates of response to acetylcholinesterase inhibitor therapy in Alzheimer’s diseaseJ Psychiatry Neurosci200328132612587847
   PubMed Web of Science ®Google Scholar
• RockwoodKFaySGormanMCarverDGrahamJThe clinical meaningfulness of ADAS-cog changes in Alzheimer’s disease patients treated with donepezil in an open-label trialBMC Neurology200772617760991
   PubMed Web of Science ®Google Scholar
• CourtneyCFarrellDGrayRLong-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): Randomised double-blind trialLancet20043632105211515220031
   PubMed Web of Science ®Google Scholar
• WinbladBWimoAEngedalK3-year study of donepezil therapy in Alzheimer’s disease: Effects of early and continuous therapyDement Geriatr Cogn Disord20062135336316508298
   PubMed Web of Science ®Google Scholar
• SmallGWKauferDMendiondoMSQuargPSpiegelRCognitive performance in Alzheimer’s disease patients receiving rivastigmine for up to 5 yearsInt J Clin Pract20055947347715853867
   PubMed Web of Science ®Google Scholar
• PirtillaTWilcockGTruyenLDamarajuCVLong-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer’s disease: multicenter trialEur J Neurol20041173474115525294
   PubMed Web of Science ®Google Scholar
• RogersSLDoodyRSPrattRDIeniJRLong-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label studyEur Neuropsychopharmacol20001019520310793322
   PubMed Web of Science ®Google Scholar
• HolmesCLovestoneSLong-term cognitive and functional decline in late onset Alzheimer’s disease: therapeutic implicationsAge Aging200332200204
   Web of Science ®Google Scholar
• LyleSGrizzellMWillmottSBenbowSClarkMJolleyDTreatment of a whole population sample of Alzheimer’s disease with donepezil over a 4-year period: lessons learnedDement Geriatr Cogn Disord20082522623118230972
   PubMed Web of Science ®Google Scholar
• WallinÅKGustafsonLSjogrenMWattmoCMinthonLFive-year outcome of cholinergic treatment of Alzheimer’s disease: Early response predicts prolonged time until nursing home placement, but does not alter life expectancyDement Geriatr Cogn Disord20041819720615211076
   PubMed Web of Science ®Google Scholar
• MinthonLWallinÅKErikssonSWattmoCAndreasenNLong-term rivastigmine treatment in a routine clinical settingActa Neurol Scand200911918018518759798
   PubMed Web of Science ®Google Scholar
• WallinÅKAndreasenNErikssonSDonepezil in Alzheimer’s disease: What to expect after 3 years of treatment in a routine clinical settingDement Geriatr Cogn Disord20072315016017312368
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationAmerican Psychiatry Association: Diagnostic and Statistical Manual of Mental Disorders4th EditionWashington, DCAmerican Psychiatric Association1994
   Google Scholar
• McKhannGDrachmanDFolsteinMKatzmanRPriceDStadlanEMClinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s DiseaseNeurology1984349399446610841
   PubMed Web of Science ®Google Scholar
• FolsteinMFFolsteinSMcHughPR“Mini-Mental state”: a practical method for grading the cognitive state of patients for the clinicianJ Psychiatry Res197512189198
   PubMed Web of Science ®Google Scholar
• RosenWGMohsRCDavisKLA new rating scale for Alzheimer’s diseaseAm J Psychiatry1984141135613646496779
   PubMed Web of Science ®Google Scholar
• LawtonMPBrodyEMAssessment of older people: Self-maintaining and instrumental activities of daily livingGerontologist196991791865349366
   PubMed Web of Science ®Google Scholar
• KnappMJKnopmanDSSolomonPRA 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s diseaseJAMA19942719859918139083
   PubMed Web of Science ®Google Scholar
• SchneiderLSOlinJTClinical global impressions in Alzheimer’s clinical trialsInt Psychogeriatr199682772888994897
   PubMedGoogle Scholar
• KnopmanDSKnappMJGraconSIDavisCSThe Clinician Interview-Based Impression (CIBI): A clinician’s global change rating scale in Alzheimer’s diseaseNeurology199444231523217991118
   PubMed Web of Science ®Google Scholar
• SternRMohsRDavidsonMA longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deteriorationAm J Psychiatry19941513903968109647
   PubMed Web of Science ®Google Scholar
• YesavageJAPoulsenABSheikhJTankeERates of change of common measures of impairment in senile dementia of the Alzheimer’s typePsychopharmacol Bull1988245315343074314
   PubMedGoogle Scholar
• HanLColeMBellavanceFMcCuskerJPrimeauFTracking cognitive decline in Alzheimer’s disease using the Mini-Mental State Examination: a meta-analysisInt Psychogeriatr20001223124710937543
   PubMed Web of Science ®Google Scholar
• WinbladBEngedalKSoininenHA 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate ADNeurology20015748949511502918
   PubMed Web of Science ®Google Scholar
• DoodyRPavlikVMassmanPRountreeSDarbyEChanWPredicting progression of Alzheimer’s diseaseAlzheimers Res Ther20102220178566
   PubMed Web of Science ®Google Scholar
• SalmonDPThalLJButtersNHeindelWLongitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinationsNeurology199040122512302381530
   PubMed Web of Science ®Google Scholar
• MendiondoMSAshfordJWKryscioRJSchmittFAModelling Mini Mental State Examination changes in Alzheimer’s diseaseStat Med2000191607161610844722
   PubMed Web of Science ®Google Scholar
• Kramer-GinsbergEMohsRCAryanMClinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary reportPsychopharmacol Bull19882434584623153508
   PubMedGoogle Scholar
• CummingsJLUse of cholinesterase inhibitors in clinical practice: evidence-based recommendationsAm J Geriatr Psychiatry20031113114512611743
   PubMed Web of Science ®Google Scholar
• WilcockGHoweIColesHA long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s diseaseDrugs Aging20032077778912875613
   PubMed Web of Science ®Google Scholar
• GreenRCSchneiderLSAmatoDAEffect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer diseaseJAMA20093022557256420009055
   PubMed Web of Science ®Google Scholar
• PakrasiSMukaetova-LadinskaEBMcKeithIGO’BrienJTClinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in NewcastleInt J Geriatr Psychiatry20031887988614533120
   PubMed Web of Science ®Google Scholar
• FarlowMRHakeAMessinaJHartmanRVeachJAnandRResponse of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progressionArch Neurol20015841742211255445
   PubMed Web of Science ®Google Scholar
• WallinÅKBlennowKZetterbergHLondosEMinthonLHanssonOCSF biomarkers predict a more malignant outcome in Alzheimer diseaseNeurology2010741531153720458070
   PubMed Web of Science ®Google Scholar
• RockwoodKDaiDMitnitskiAPatterns of decline and evidence of subgroups in patients with Alzheimer’s disease taking galantamine for up to 48 monthsInt J Geriatr Psychiatry20082320721417621382
   PubMed Web of Science ®Google Scholar
• KrögerEvan MarumRSouvereinPEgbertsTDiscontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort studyDrugs Aging20102766367520658794
   PubMed Web of Science ®Google Scholar
• RockwoodKSize of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s diseaseJ Neurol Neurosurg Psychiatry20057567768515090558
   PubMed Web of Science ®Google Scholar
• ReynishECortesFAndrieuSThe ICTUS Study: A prospective longitudinal observational study of 1,380 AD patients in EuropeNeuroepidemiology200729293817898521
   PubMed Web of Science ®Google Scholar
• ArbusCGardetteVBuiEAntidepressant use in Alzheimer’s disease patients: results of the REAL.FR cohortInt Psychogeriatr20102212012819735591
   PubMed Web of Science ®Google Scholar
• HerrmannNBinderCDalzielWSmythSCamachoFPersistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database studyDrugs Aging20092640340719552492
   PubMed Web of Science ®Google Scholar
• DoodyRSGeldmacherDSGordonBfor the Donepezil Study GroupOpen-label, multicenter, Phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer diseaseArch Neurol20015842743311255446
   PubMed Web of Science ®Google Scholar
• GrossbergGIrwinPSatlinAMesenbrinkPSpiegelRRivastigmine in Alzheimer disease – efficacy over two yearsAm J Geriatr Psychiatry20041242043115249280
   PubMed Web of Science ®Google Scholar
• RaschettiRMagginiMSorrentinoGCMartiniNCaffariBVanacoreNA cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s diseaseEur J Clin Pharmacol20056136136815912389
   PubMed Web of Science ®Google Scholar
• BullockRTouchonJBergmanHRivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year periodCurr Med Res Opin2000211317132716083542
   PubMed Web of Science ®Google Scholar
• MohsRCDoodyRSMorrisJCA 1-year, placebo-controlled preservation of function survival study of donepezil in AD patientsNeurology2001548148811502917
   PubMed Web of Science ®Google Scholar